Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00043277 · ClinicalTrials.gov registry record · Phase 2
Study Of Angiomax In Infants Under Six Months With Thrombosis
A Phase 2 study of Thrombosis, sponsored by The Medicines Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT00043277 is a Phase 2 study of Thrombosis that has completed, run by The Medicines Company. The registered enrollment target is 25 participants, below the 469-participant average among 28 other Thrombosis trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00043277, a Phase 2 study of Thrombosis, has completed, sponsored by The Medicines Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
The goals of this study are: 1. To assess the safety of bivalirudin in infants under six months with arterial or venous thrombosis; 2. To determine the dose of bivalirudin required to achieve adequate anticoagulation as measured by the activated clotting time (ACT) or activated partial thromboplastin time (aPTT) in Infants Under Six Months with arterial or venous thrombosis; 3. To determine the outcome of patients on bivalirudin with respect to thrombus resolution and bleeding complications compared to patients on unfractionated heparin (UH) or low molecular weight heparin (LMWH).
Conditions Studied
Interventions
- DRUG Angiomax (bivalirudin)
Study Locations (1)
California
- Children's Hospital of Orange County - Orange
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2002-08 |
| Est. Completion | 2004-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00043277
The ClinicalTrials.gov registry entry for NCT00043277 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 469-participant average among 28 other Thrombosis trials with a reported enrollment target (95% lower). The listed sponsor is The Medicines Company, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Thrombosis appearing as the primary indexed condition, and to 1 intervention - of which Angiomax (bivalirudin) is the first listed.
NCT00043277 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00043277 about?
NCT00043277 is a clinical study titled "Study Of Angiomax In Infants Under Six Months With Thrombosis". The goals of this study are: 1. To assess the safety of bivalirudin in infants under six months with arterial or venous thrombosis; 2. To determine the dose of bivalirudin required to achieve adequate anticoagulation as measured by the activated clotting time (ACT) or activated partial thromboplast...
What is the current status of trial NCT00043277?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2002-08. Estimated completion is 2004-12.
What conditions does trial NCT00043277 study?
This clinical trial studies the following conditions: Thrombosis.
What interventions are being tested in trial NCT00043277?
The interventions under investigation include: Angiomax (bivalirudin) (DRUG).
Who is sponsoring clinical trial NCT00043277?
This trial is sponsored by The Medicines Company, which has 35 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00043277 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thrombosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety and Efficacy Study of a Protease Activated Receptor-4 Antagonist Being Tested to Reduce the Chances of Having Additional Strokes or "Mini Strokes"
COMPLETED · Phase 2
-
A Study of DU-176b in Preventing Blood Clots After Hip Replacement Surgery
COMPLETED · Phase 2
-
Alfimeprase for Thrombolysis in Acute Peripheral Arterial Occlusion
COMPLETED · Phase 2
-
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
RECRUITING
-
Positron Emission Tomography (PET) Imaging of Thrombosis
RECRUITING · Phase 1
-
Pharmacogenomics of Warfarin in Hispanics and Latinos
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.